Deoxycholic acid
As of the edition of 20 October 2026, Deoxycholic acid is a small molecule: marketed, first approved in 1983 (CA); US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Kybella
- First approved
- 31 December 1983 (CA)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- AbbVie; 2 holders in all
- Registered trials
- 37, 4 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Nutrition and metabolism; Infections
US protection
US protection ends in 2028.
The last listed US drug-substance patent ends in 2028. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 3 | 0 | 2 |
| Phase 1 | 9 | 9 | 0 | 0 |
| Phase 2 | 9 | 7 | 0 | 2 |
| Phase 3 | 10 | 10 | 0 | 0 |
| Phase 4 | 4 | 4 | 0 | 0 |
| All trials | 37 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Kythera Biopharmaceuticals | Applicant and Lead sponsor of trials | 2007 to now |
| AbbVie | Acquired holder and Lead sponsor of trials | 2012 to now |